The FDA Recently Approved the Promising New Pancreatic Cancer Treatment Daraxonrasib
With recent FDA approval of Rasonque (Daraxonrasib), a RAS inhibitor, a promising new treatment option is now available for eligible NYOH patients with metastatic pancreatic cancer.
Dr. Madhavi Kambam is a Medical Oncologist and Hematologist at New York Oncology Hematology, who specializes in gastrointestinal cancers, including pancreatic cancer. She was the physician lead in NYOH’s Expanded Access Program for Daraxonrasib, providing patients with access to this investigational therapy prior to its FDA approval.
Below, Dr. Kambam explains this breakthrough treatment for pancreatic cancer, the FDA's recent approval, and how the targeted therapy works differently to attack cancer. She also explains why it works differently from traditional chemotherapy, and what patients may be eligible.
If you or a loved one is diagnosed with pancreatic cancer, talk with your oncology care team to see if this treatment could be an option for you. For a second opinion or to be seen by a pancreatic cancer specialist, contact NYOH.
The FDA recently approved Daraxonrasib. Why is this such a significant development for patients with pancreatic cancer?
The FDA's recent approval of Daraxonrasib marks a major step forward for patients with metastatic pancreatic cancer. For the first time, we have an approved targeted medicine that directly inhibits RAS, a key driver of tumor growth in most pancreatic cancers. This provides a new treatment option for patients facing a disease that has historically had limited treatment options.
Can you explain, in simple terms, how Daraxonrasib works and what it targets in cancer cells?
Daraxonrasib works by targeting RAS proteins, which play an important role in driving the growth of pancreatic cancer. The vast majority of pancreatic cancers have mutations in KRAS, a member of the RAS family. Daraxonrasib is designed to inhibit active RAS signaling, helping interfere with the signals cancer cells use to grow and survive.
Dr. Kambam was recently interviewed about Daraxonrasib on WAMC Northeast Public Radio’s Northeast Notebook podcast. Listen here.
What makes this drug different from previous pancreatic treatment options, and why are oncologists so excited about it?
What makes Daraxonrasib different from traditional chemotherapy is the way it attacks cancer. While chemotherapy works broadly against rapidly dividing cells, targeted therapies are designed to interfere with specific proteins or pathways that cancer cells depend on for growth. Daraxonrasib targets RAS, an important driver of pancreatic cancer, offering a new approach to treating the disease.
Which patients may be eligible for daraxonrasib, and how can they find out if it might be an option for them?
Daraxonrasib is approved for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. Patients should speak with their oncology care team to determine whether Daraxonrasib may be an appropriate treatment option for them.
For more than 30 years, NYOH has been a leader in cancer research. Our patients have participated in clinical trials leading to more than 100 FDA-approved cancer treatments. Home to the region’s largest cancer research program, we offer access to groundbreaking therapies—often before they’re available anywhere else.
Current research trials available at NYOH
More about our research program